Year in Review

Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease

2017 saw the emergence of a new era in renoprotective medicine for diabetic kidney disease with reports of promising renal outcomes with the sodium–glucose cotransporter 2 (SGLT2) inhibitors empagliflozin and canagliflozin from follow-up analyses of the EMPA-REG OUTCOME trial and the CANVAS Program, respectively, and with use of the glucagon-like peptide 1 (GLP1) agonist liraglutide in the LEADER trial.

  • Subscribe to Nature Reviews Nephrology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

  2. 2.

    et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).

  3. 3.

    et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

  4. 4.

    et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

  5. 5.

    et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).

  6. 6.

    & Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60, 215–225 (2017).

  7. 7.

    et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation , (2017).

  8. 8.

    et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5, 610–621 (2017).

Download references

Author information


  1. Department of Medicine, Division of Nephrology, Würzburg University Hospital, Oberdürrbacherstr. 6, 97080 Würzburg, Germany.

    • Christoph Wanner


  1. Search for Christoph Wanner in:

Competing interests

C.W. has received honoraria for consultancy and speaking from Boehringer-Ingelheim, Sanofi-Genzyme, Astra-Zeneca and Mitsubishi Pharma.

Corresponding author

Correspondence to Christoph Wanner.